Skip to content

BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation, Tax Credit, Expiration Of Research And Development Tax Credits, Amount

Effective Income Tax Rate Reconciliation, Tax Credit, Expiration Of Research And Development Tax Credits, Amount at other companies

Paycom Software logo
Paycom SoftwarePAYC
$2.3M+16.5%
Proto Labs logo
Proto LabsPRLB
$136.75K
Albany International Inc. logo
Albany International Inc.AIN
$251K
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$844.25K
Terex logo
TerexTEX
$500K0.0%
PayPal Holdings, Inc. logo
PayPal Holdings, Inc.PYPL
$24.75M

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditExpirationOfResearchAndDevelopmentTaxCreditsAmount.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, amount?
BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, amount of -$893.5K in Q4 2025.
How has BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, amount changed year-over-year?
BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, amount decreased by 42.2% year-over-year, from -$628.5K to -$893.5K.
What is the long-term trend for BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, amount?
Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, amount has grown at a 107.4% compound annual growth rate (CAGR), from -$831K to -$3.57M.
What does effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, amount mean?
The financial impact of the expiration of previously recognized research and development tax credits that were not utilized within the statutory timeframe. This metric highlights potential inefficiencies in tax planning or the inability to fully monetize R&D tax incentives.